Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

From the Telegraph

A story is one of the most powerful drivers in the stock market

Aim-listed BioProgress is one of the best current examples. This company has developed a range of patented methods to replace conventional gelatine pills, which could revolutionise pharmaceutical drugs and dietary supplements. Its technology has other applications and major companies are signing agreements. Since BioProgress floated on Aim 16 months ago the story has seized attention and created strong momentum in its shares. In nine months, the price soared from 22p to near 160p.


Notice how a story is most potent when a share has little or no financial record. Last Wednesday, BioProgress declared interims to end-June that showed a gross profit of 430,000 on turnover of 992,000, but a pre-tax loss of 3.8m as the company continues to invest in development. Since underlying progress looks promising, this attractive story means that at 131p, a share BioProgress is capitalised at 152m.

But the lack (as yet) of a benchmark for financial value meant bear raiders hammered the shares down to 57p recently. Unless you know what you are doing and can stomach the risks and volatility, this is how private investors become easy meat.

I treat a share as speculative where it is hard to be sure of the financial values. I prefer not to be weighted in speculative shares, as they get hit worst of all in a general financial panic or bear market. You never quite know when or from where the next shock will come.

But enterprising players can still scrutinise a good story and consider what aspects of the business make the risks worth taking. BioProgress continues to win customers and its licensing approach is attractive. Yet valuing the company remains subjective. The shares are a market makers' dream, heavily traded.

To me, a sensible approach is to recognise the extent you want to engage in speculation. It can have a place in your portfolio, so long as you are adept at trading and apply discipline such as stop losses. But avoid chasing a lot of exciting stories, which lead to high transaction costs and a capital gains tax accounting headache. It is all very well thinking: "If only I'd made that switch" in hindsight. You can make astute trades in the short term yet end up no better (or even worse) off, flitting from one story to the next.

As for BioProgress, be mindful that some of its ardent holders promoting the shares do not recognise risks. Perhaps a reason why the shares don't get a lot of coverage is that unless a commentator proclaims: "Five pounds by Christmas!", he is liable to face an angry mob of BioProgress enthusiasts. Life is too short for this.

A story is one of the most powerful drivers in the stock market | Can history not be repeated? | Oil still rising



Can history not be repeated?

Superscape, the interactive 3D software group, is a useful example how a story can adapt and revive.

It is usually best to sell shares in a loss-making company as soon as its story changes for the worse. Superscape's 10-year chart shows the depths to be avoided, even if it means selling into a 20 to 30 per cent fall.

Some investors admit their worst mistakes have been buying a share after it had fallen, only to realise it is a chronic poor performer. Superscape's chart illustrates this, despite showing how alertness to the changing story can yield big gains for traders.

Superscape's technology has existed for some 20 years and it has yet to deliver any profit. The company owes its continuing existence to the goodwill of investors who have kept refinancing it. But this time around I genuinely believe Kevin Roberts and his team have a winning strategy.

Well, I would say that, wouldn't I, as a holder. But like BioProgress the extent of commercial momentum (in recent news, and underlying prospects) improves the probability that this is now a growth share.

Once again the challenge is valuation. At 44.5p Superscape is capitalised at 55m, which initially seems high enough while the market for mobile gaming (the group's current focus) is evolving. It is vast but liable to change, and the time-honoured principle applies that until there is a financial record it is hard to judge how the story boils down to earnings.

Superscape's broker projects a 5.3m loss in the year to end-January 2005 improving to a 700,000 loss in 2005/06. There may be better news; the snag is that it may not be in Superscape's commercial interests to reveal much about the deals it is signing when announcing interims on October 15.

Although the guessing game is likely to continue, I intend to stay with this share.

http://tinyurl.com/6b8s7

i agree with much of what has been said above but it fails to note one thing. All new technology shares will perform between good and bad until the technology comes to the market, if it all it does come to the market. Surely this is the decision one has to make now with bprg and sps, ' are these companies going to turn technology into finance revenue'.

If sps had this technology 20 years (ie 3d games) surely there was not the platform to use that technology, now there is with the introduction of 3g phones AND THE PROMISE THEY SHOULD BE AVAILABLE THIS XMAS. I think both these companies are just starting out on a whole new adventure. nothing is guaranteed but good luck to holders.

Big Al,
Am of course still holding. As on AIM, holding for 2 years cuts my potentially large payment to the taxman from 40% to 10%. Personally I reckon BPRG will get taken out but not for less than 3 and within a year or so. Just back from a sunny week in Benidorm, so with the SEO announcement the holiday seemed pretty cheap ;-)

news out today...buy,buy,buy!!!!

http://tinyurl.com/5a9y3

Erm, isn't this the same news as last week's?

Signed, A Holder.

What news is this? Please advise, price moving today has someone got wind of something?

patience my friends patience...you will be rewarded even more!!!!

More wind this coming week

123.75p today...on the uptrend

Something in the wind, large volume of buys around 12 o'clock onwards, me thinks there is something happening... Aint getting my shares at this price, lol. Good luck to all.

BioProgress CEO Hind sells 300,000 shares, cuts stake to 0.21 pct
AFX


LONDON (AFX) - BioProgress PLC, which provides delivery systems for the pharmaceutical oral dosage markets, said chief executive Graham Hind sold 300,000 shares in the company at an average price of 1.25 stg apiece.

Hind now holds 247,773 BioProgress shares, representing a stake of 0.21 pct. He also holds 3,005,889 options with exercise prices that range from 19-84 pence.

These are the first shares in BioProgress Hind has sold to date, and the proceeds will be used for personal purposes, the company said.

Hind as no plans to sell further shares in BioProgress in the foreseeable future, it added.

newsdesk@afxnews.com

ak/

The AFX summary conveniently and misleadingly omitted the phrase:

"....including the provision of cash to enable the exercising of share options in BioProgress which expire on December 31st 2004."

after the bit about his using the proceeds for personal purposes. I would have thought that was of interest to shareholders! Are these journos paid for their work?

Bones-where did you get the rest of it?

It was on the RNS, bit of poor reporting from AFX

http://www.uk-wire.com/cgi-bin/articles/200410181600011904E.html

Janus-tks

Small delay

BioProgress PLC
20 October 2004


Press Release 20 October 2004

BioProgress plc

('BioProgress' or 'the Company')

NASDAQ listing

BioProgress plc, a provider of innovative delivery mechanisms for the
pharmaceutical oral dosage markets, announces that due to administrative
procedures required by the NASDAQ National Market ('NASDAQ'), the Company
expects its American Depository Receipts (ADRs) to now be listed on NASDAQ by no
later than Friday 22nd October 2004.

- Ends -

Forward-Looking Information

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934. This announcement contains certain 'forward-looking
statements' within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and are
subject to uncertainty and changes in circumstances. Actual results may vary
materially from the expectations contained in the forward-looking statements.
The forward-looking statements in this release include statements addressing
future financial and operating results. An important factor that could cause the
statements made in this release to differ is the possible impact of fluctuating
exchange rates for the pounds sterling and the U.S. dollar. Other important
factors pertinent to the business of the company that could cause actual results
to differ are discussed under the caption 'Forward-Looking Statements' in the
Company's Form 20-F Annual Report for the year ended December 31, 2003 and in
subsequent filings. The Company is under no obligation to (and expressly
disclaim any such obligation to) update or alter its forward-looking statements
whether as a result of new information, future events or otherwise.


- Ends -

For further information:

BioProgress plc
Graham Hind, Chief Executive Tel: +44 (0) 1354 655674

grahamhind@bioprogress.com

From amongst the dross at the other place


http://www.advfn.com/cmn/fbb/thread.php3?id=6121178&from=83098



sthomson2 - 20 Oct'04 - 13:56 - 83087 of 83098


CHECK THIS OUT.... JUST CAME OVER MY BLOOMBERG

Page 1 of 3
MWR 08:46 AXM Pharma Secures Exclusive Distribution Rights for Dissolving

AXM Pharma Secures Exclusive Distribution Rights for BioProgress
Soluleaves(TM) In-the-Mouth Dissolving Film Oral Drug Delivery
Technology for Prescription and OTC Markets for Its Sunkist Brand
Nutritional Supplements and for AXM House Brands in China

NEWPORT BEACH, CA -- (MARKET WIRE) -- 10/20/04 -- AXM Pharma, Inc.
(AMEX: AXJ) announced today that the Company has acquired the
exclusive distribution rights in China to certain formulations of the
Soluleaves(TM) oral drug delivery technology using
dissolve-in-the-mouth films developed by BioProgress plc (LSE: AIM
BPRG) The agreement includes the option to extend the distribution
rights throughout Asia. The products will be manufactured by the
BioProgress subsidiary BioTec Films LLC and will be distributed by
AXM Pharma under the Sunkist brand and under AXM house brands.

The market for in-the-mouth dissolving films was pioneered by the
Warner Lambert division of Pfizer in the United States where sales of
Listerine breath freshener in the USA were reported by Information
Resources, Inc. to reach $200 million in 2001. The consumer-ready
acceptance of the in-the-mouth dissolving film concept quickly
resulted in product introductions from Wrigleys and Kraft foods under
the Altoids mint brand. BioProgress plc, through its BioTec films
subsidiary in Tampa, Florida, has successfully developed vitamin and
nutritional products in this delivery mechanism and has several
patents granted and in application for innovative processes which
enable the delivery of pharmaceutical drugs in soluble film.

The market for advanced drug delivery systems is expected to grow
from $16.28 billion in 2000 to $27.35 billion in 2005 in the United
States according to a Business Communications Company report. Drug
delivery technologies make medicines more convenient and acceptable to
patients by simplifying the dosing regimen and improving
administration, which helps to improve patient outcomes, quality of
life and reduce costs.

Oral delivery of drugs using fast dissolve in-the-mouth films is
ideal for line extension of existing drugs and for drugs that no
longer have patent protection. This technology provides a
competitive advantage to companies with competing drugs that have
very little difference in therapeutic effect. By offering a unique
formulation that tastes good and is easy to take anytime, anywhere
and without water or fluids, a drug company has a distinct advantage
over its competition.

Market research at CIMA Labs shows that a significant percentage of
consumers prefer orally dissolving drug delivery to conventional
pills, tablets and liquids. 70% of consumers studied would ask for
and purchase oral dissolving drugs, and nearly 90% said they
preferred this to conventional drug delivery.

-----------------------------====================------------------------------


Page 2 of 3


"A key component of success in orally dissolving drug delivery is
good taste. This makes taking medication easier, especially for
children and the elderly, who traditionally have difficulties
swallowing more conventional dosage forms," said Peter Cunningham,
President and CEO of AXM Pharma.

AXM Pharma's technology will be beneficial in taste masking
prescription and over-the-counter drugs. Additional research at CIMA
Labs shows that patients prefer good-tasting formulations to bland or
non-flavored products. According to a recent article in Drug Delivery
Technologies, "The main factor that will differentiate the drug
companies fighting for market share in an increasingly crowded
pharmacy will be taste."

Faced with soaring R&D Costs, an impending onslaught of patent
expirations, mega-merger mania, and increasing consumer demands for
improved medications, drug companies are relying more heavily on
advanced drug delivery technologies to help sustain high growth and
profit margins. With more than 50 patents expiring by 2005,
including a number of blockbuster drugs, they are under intense
pressure to replace these losses with new or improved drugs.

Developing a generic requires use of sophisticated drug delivery
technologies that must not only match the pharmacokinetic profile of
the reference drug, but must also avoid the innovator's patents. Oral
dissolving drug delivery's ease, flexibility and rapid development
time can increase the chances of a generic being first to market.

Drug companies can use drug delivery technology to extend exclusivity
on their drugs by replacing sales of a product with an expiring patent
with a different chemical entity or brand name.

AXM Pharma Inc., http://www.axmpharma.com, through its wholly owned
subsidiary, Werke Pharmaceuticals, Inc., is the 100% owner of AXM
Pharma Shenyang, Inc. ("AXM Shenyang"), a Wholly Foreign Owned
Enterprise ("WFOE") under the laws of the People's Republic of China.
AXM Shenyang is located in the City of Shenyang, in the Province of
Liaoning, China. AXM Shenyang and its predecessor company Shenyang
Tianwei Pharmaceutical Factory, Ltd. ("STPF"), has an operating
history of approximately 10 years. AXM Shenyang historically has been
a manufacturer and distributor of proprietary and generic
pharmaceutical products, which include injectables, capsules,
tablets, liquids and medicated skin products for export and domestic
Chinese sales. AXM Shenyang is currently awaiting re-licensing of its
pharmaceutical products pursuant to new national licensing
requirements for pharmaceutical products in China and certification
of its new factory. Approval of the re-licensing and factory
certification is expected in the fourth quarter of 2004. For
additional information on AXM Pharma Inc, please visit

-----------------------------====================------------------------------


Page 3 of 3

http://www.iccinfo.com or call Investor Communications Company, LLC
at 708-447-6834.

Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995: The statements contained in this news release include
certain predictions and projections that may be considered
forward-looking statements under securities law. These statements
involve a number of important risks and uncertainties that could
cause actual results to differ materially including, but not limited
to, the performance of joint venture partners, as well as other
economic, competitive and technological factors involving the
Company's operations, markets, services, products and prices. With
respect to AXM, except for the historical information contained
herein, the matters discussed in this news release are
forward-looking statements involving risks and uncertainties that
could cause actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties
include, but are not limited to, AXM's extremely limited operating
history, uncertainties related to the Company's access to additional
capital, competition and dependence on key management.



Contact Information:
Tom Bostic
Investor Communications Company, LLC
(708) 447-6834
Provider ID: 04074458
-0- (MWR) Oct/20/2004 12:46 GMT

At last - here we go!!!

Price going up-why no rns on this?

Always difficult to determine why the price has shot up today after a poor start, except to say that the NASDAQ listing, although delayed, is good news, and the market is waking up to the potential of the US tech savvy investors piling into this stock in a few days time!